Back to list

Medicilon's chemistry department consists of synthetic chemistry services and medicinal chemistry services. Clients can work with us on a Fee for Service or Full Time Equivalent basis.

In 2021, Medicilon established the International Discovery Service Unit (IDSU). The IDSU provides global pharmaceutical companies with high quality, efficient and cost-effective chemistry synthesis design and production and medicinal chemistry. The IDSU supports the discovery and delivery of clinical candidate compounds forglobal drug research and development.

ADC Drug Discovery

Medicilon has 50+Payloads,200+Linkers,30+Payloads+Linkers. Up until the end of 2022, Medicilon undertook more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of May 8, 2023, Medicilon has successfully assisted 17 ADC drugs to obtain clinical approval, and more than 10 ADC projects are in development.

PROTAC Drug Discovery

Medicilon has access to many of the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition to having established a linker library containing hundreds of diverse molecules.As of the end of June 2023, Medicilon has successfully assisted 5 PROTAC drugs to abtain clinical approval, and more than 20 PROTAC projects are under development.

Nucleic Acid Drug Discovery

The Medicilon nucleotide drug R&D platform can provide a one-stop option for monomer synthesis and modification; oligonucleotide synthesis; delivery system synthesis and oligonucleotide conjugate synthesis. The siRNA library that has been built has a rich monomer inventory anda large monomer synthesis building block library, to support the synthesis of various modified monomers.